Morgan Stanley analyst Cecilia Furlong maintains Axonics (NASDAQ:AXNX) with a Overweight and raises the price target from $73 to $80.
Cognition Therapeutics Presents Complete EEG Findings From SEQUEL Study Of CT1812 In Mild-To-Moderate Alzheimer’s Disease At CTAD
Cognition Therapeutics, Inc., (NASDAQ:CGTX), (the "Company" or "Cognition") announced that Willem de Haan, M.D., Ph.D., a neurologist and senior researcher at the Amsterdam University Medical Centers' Alzheimer Center,
